Therapeutic Approach

Archive: August, 2017

Ritter Pharmaceuticals Announces Phase 3 Plans after its End of Phase 2 Meeting with FDA on RP-G28 for Lactose Intolerance

Company has incorporated guidance from FDA on key elements of its Phase 3 program to support a New Drug Application (NDA) for RP-G28 Los Angeles, California, August 18, 2017 – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (the “Company”), a developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced its […]

Leave Your Comments »

Ritter Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update

LOS ANGELES (August 7, 2017) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today reported financial results for the second quarter ended June 30, 2017. Recent Highlights Announced that the FDA has agreed to schedule […]

Leave Your Comments »

Ritter Pharmaceuticals Reports Further Analysis from its Phase 2b/3 Trial Results Demonstrating Significant Reductions in Lactose Intolerance Symptoms

Analysis shows clinically meaningful benefit from symptoms, global patient-reported and real-world assessments Los Angeles, California, August 3, 2017 – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (the “Company”), a developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases today announced additional findings and data analysis from its Phase 2b/3 study designed to evaluate […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD